AbbVie Inc (ABBV)vsTeleflex Incorporated (TFX)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
TFX
Teleflex Incorporated
$133.30
-1.64%
HEALTHCARE · Cap: $5.90B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2969% more annual revenue ($61.16B vs $1.99B). ABBV leads profitability with a 6.9% profit margin vs -45.5%. TFX appears more attractively valued with a PEG of 0.16. TFX earns a higher WallStSmart Score of 67/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
TFX
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Margin of Safety
+16.7%
Fair Value
$128.38
Current Price
$133.30
$4.92 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Growing faster than its price suggests
Strong operational efficiency at 40.6%
Earnings expanding 64.1% YoY
Reasonable price relative to book value
19.4% revenue growth
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
ROE of 1.6% — below average capital efficiency
Premium valuation, high expectations priced in
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : TFX
The strongest argument for TFX centers on PEG Ratio, Operating Margin, EPS Growth. Revenue growth of 19.4% demonstrates continued momentum. PEG of 0.16 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : TFX
The primary concerns for TFX are Return on Equity, P/E Ratio, Profit Margin. A P/E of 101.8x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a value stock while TFX is a growth play — different risk/reward profiles.
TFX carries more volatility with a beta of 0.83 — expect wider price swings.
TFX is growing revenue faster at 19.4% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
TFX scores higher overall (67/100 vs 63/100) and 19.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Teleflex Incorporated
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?